Status | Study |
Not yet recruiting |
Study Name: TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors Condition: Neuroendocrine Tumors Neuroendocrine Carcinoma Temozolomid Date: 2017-03-09 Interventions: Drug: TEMCAP Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a |
Recruiting |
Study Name: FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Condition: Gastro-enteropancreatic Neuroendocrine Tumor Pancreatic Cancer Date: 2017-02-02 Interventions: Drug: FOLFIRINOX The FOLFIRINO |
Not yet recruiting |
Study Name: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors Condition: Gastroenteropancreatic Neuroendocrine Tumors Date: 2017-02-01 Interventions: Drug: Somatuline Depot Somatul |
Recruiting |
Study Name: Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Condition: Gastroenteropancreatic Neuroendocrine Tumor Date: 2016-12-30 |
Recruiting |
Study Name: Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors Condition: Gastroenteropancreatic Neuroendocrine Tumor Lung Neuroendocrine Date: 2016-10-27 Interventions: Procedure: NETest 5 mL of blood will be drawn from participants for testing. |
Completed |
Study Name: Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours Condition: Gastroenteropancreatic Neuroendocrine Tumours Date: 2016-05-27 |
Withdrawn |
Study Name: Pasireotide Treatment for Neuroendocrine Tumor Condition: Gastro-enteropancreatic Neuroendocrine Tumor Date: 2016-05-16 Interventions: Drug: Pasireotide Pasireotide |
Recruiting |
Study Name: Community-based Neuroendocrine Tumor (NET) Research Study Condition: Gastroenteropancreatic Neuroendocrine Tumors Date: 2016-04-01 |
Recruiting |
Study Name: Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs Condition: Gastroenteropancreatic Neuroendocrine Tumors Date: 2015-12-11 Interventions: Other: This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician. |
Not yet recruiting |
Study Name: [68 Ga]-DOTANOC PET/CT in GEP-NETs Condition: Gastroenteropancreatic Neuroendocrine Tumors Date: 2015-11-09 Interventions: Drug: [68Ga]-DOTANOC PET/CT |